C19orf45 Inhibitors
C19orf45 inhibitors operate by targeting signaling pathways that indirectly modulate the functional activity of C19orf45. The PI3K/AKT pathway is one such target, where inhibitors like LY294002 act to decrease AKT phosphorylation, thereby potentially reducing C19orf45 activity if it is downstream of AKT. This mechanism illustrates how targeted disruption of a signaling cascade can lead to diminished activity of proteins that are regulated by that pathway. Similarly, inhibitors of the MAPK pathway, such as PD0325901, Sorafenib, and Selumetinib, can diminish the phosphorylation of MEK or ERK, leading to reduced activity of C19orf45 if it is under the control of MAPK signaling. These compounds exemplify how inhibiting key regulatory kinases within a signaling network can decrease the activity of a particular protein of interest.
Moreover, the influence of mTOR inhibitors like Rapamycin and AZD8055 on C19orf45 demonstrates another dimension of pathway-based inhibition. By specifically inhibiting mTORC1 or both mTOR complexes, these inhibitors can suppress downstream signaling
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
A PI3K inhibitor that prevents the phosphorylation and activation of downstream targets such as AKT. If C19orf45 is downstream of PI3K/AKT signaling, inhibition by Wortmannin would result in decreased C19orf45 activity due to reduced AKT signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that prevents mTORC1 activation. If C19orf45 is regulated by mTOR signaling, Rapamycin would inhibit this pathway, leading to decreased C19orf45 activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
An inhibitor of MEK1/2, which are upstream of ERK in the MAPK pathway. If C19orf45 is regulated by the MAPK/ERK pathway, U0126 would inhibit MEK, leading to reduced ERK activation and therefore decreased C19orf45 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor similar to Wortmannin. LY294002's inhibition of PI3K would reduce AKT activation, potentially leading to a decrease in C19orf45 activity if it is involved in the PI3K/AKT pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A selective inhibitor of MEK1/2, PD98059 works upstream of ERK and can inhibit the MAPK pathway. If C19orf45 relies on the MAPK/ERK pathway for activation, PD98059 would decrease its activity by inhibiting this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, which is part of the MAPK family. If C19orf45 is activated as part of a JNK signaling pathway, SP600125 would inhibit JNK activity and decrease C19orf45 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor. If C19orf45 is downstream of the p38 MAPK pathway, inhibition by SB203580 would lead to decreased C19orf45 activity. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
A Src family kinase inhibitor. If C19orf45 is regulated by Src family kinases, inhibition by PP2 would reduce C19orf45 activity by inhibiting Src kinase activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
A broad inhibitor of Src family kinases and BCR-ABL. Dasatinib's inhibition of these kinases can lead to decreased C19orf45 activity if it is regulated by Src or BCR-ABL signaling. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
An EGFR inhibitor that blocks EGFR tyrosine kinase activity. If C19orf45 activity is dependent on EGFR signaling, inhibition by Gefitinib would result in decreased C19orf45 activity. | ||||||